Insight Molecular Diagnostics Inc. (IMDX) Financial Statements
Industry: In Vitro & In Vivo Diagnostic Substances
In fiscal 2025, Insight Molecular Diagnostics reported revenue of $4.1M, up 115.6% from $1.9M the year before. Net income was -$50.2M (a -1238.5% net margin), or -$1.65 per diluted share. Gross margin was 56.7% and operating margin was -1260.8%. Operating activities generated -$22.2M of cash, leaving -$25.4M of free cash flow. At fiscal year end, Insight Molecular Diagnostics held $25.8M in total assets against $57.2M in total liabilities, including $11.6M of cash and equivalents.
Open the full interactive Insight Molecular Diagnostics financials → Quarterly statements, key ratios, valuation history and price charts.
Insight Molecular Diagnostics Key Stats
| Share Price | $2.99 |
|---|---|
| Market Cap | $109.9M |
| Revenue YoY Growth | +115.6% |
| 52-Week Range | $2.55 – $8.48 |
| Shares Outstanding | 36.8 million (basic, 2026 Q2) |
Insight Molecular Diagnostics Income Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $1.2M | $7.7M | $958,000 | $1.5M | $1.9M | $4.1M |
| Gross Profit | -$639,000 | $188,000 | -$18,000 | $413,000 | $740,000 | $2.3M |
| Operating Income | -$29.7M | -$74.2M | -$18.0M | -$25.1M | -$61.0M | -$51.1M |
| Pre-Tax Income | -$31.2M | -$73.4M | -$18.6M | -$24.9M | -$60.7M | -$50.2M |
| Income Tax | -$1.3M | -$9.3M | $54.3M | $2.9M | $0 | $0 |
| Net Income | -$29.9M | -$64.1M | -$72.9M | -$27.8M | -$60.7M | -$50.2M |
| Diluted EPS | -$9.20 | -$14.40 | — | -$3.75 | -$4.66 | -$1.65 |
Insight Molecular Diagnostics Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $260,000 | $1.1M | $32,000 | $239,000 |
| Net Income | -$10.9M | -$23.0M | -$4.3M | -$11.3M |
| Diluted EPS | -$0.34 | -$0.75 | -$0.12 | -$0.31 |
Insight Molecular Diagnostics Balance Sheet
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $7.1M | $35.6M | $20.0M | $9.4M | $8.6M | $11.6M |
| Current Assets | $9.2M | $39.1M | $25.5M | $10.7M | $11.8M | $15.3M |
| Total Assets | $55.4M | $159.6M | $100.1M | $74.9M | $35.1M | $25.8M |
| Current Liabilities | $9.0M | $14.1M | $12.1M | $7.2M | $7.3M | $12.1M |
| Total Long-Term Debt | $3.9M | — | — | — | — | — |
| Total Liabilities | $21.9M | $94.3M | $60.5M | $49.3M | $47.4M | $57.2M |
| Shareholders' Equity | $33.5M | $65.2M | $34.3M | $20.5M | -$12.3M | -$31.5M |
Insight Molecular Diagnostics Cash Flow Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | -$26.0M | -$35.9M | -$45.6M | -$23.3M | -$20.7M | -$22.2M |
| Cash From Investing | -$11.7M | -$14.0M | -$4.3M | -$932,000 | -$512,000 | -$3.2M |
| Cash From Financing | $22.8M | $78.4M | $35.8M | $12.2M | $20.4M | $28.1M |
| Free Cash Flow | -$27.2M | -$38.2M | -$49.9M | -$23.6M | -$21.2M | -$25.4M |
Figures from Insight Molecular Diagnostics' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Insight Molecular Diagnostics financials page for every line item.
Insight Molecular Diagnostics Company Profile
| Ticker | IMDX |
|---|---|
| Exchange | Nasdaq |
| Industry | In Vitro & In Vivo Diagnostic Substances |
| Headquarters | Nashville, Tennessee |
| Incorporated in | California |
| Fiscal Year End | December 31 |
| SEC Filer Category | Non-accelerated filer, smaller reporting company |
| SEC CIK | 0001642380 |
Frequently Asked Questions
What was Insight Molecular Diagnostics' revenue in fiscal 2025?
Insight Molecular Diagnostics (IMDX) reported revenue of $4.1M for fiscal 2025.
What is Insight Molecular Diagnostics' annual revenue history?
Insight Molecular Diagnostics' annual revenue by fiscal year: 2020: $1.2M; 2021: $7.7M; 2022: $958,000; 2023: $1.5M; 2024: $1.9M; 2025: $4.1M.
What was Insight Molecular Diagnostics' net income in fiscal 2025?
Insight Molecular Diagnostics reported net income of -$50.2M for fiscal 2025.
What was Insight Molecular Diagnostics' earnings per share (EPS) in fiscal 2025?
Insight Molecular Diagnostics' diluted EPS was -$1.65 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Insight Molecular Diagnostics generate in fiscal 2025?
Insight Molecular Diagnostics generated -$25.4M of free cash flow in fiscal 2025.
What was Insight Molecular Diagnostics' revenue last quarter?
In its most recent reported quarter (2026 Q2), Insight Molecular Diagnostics reported revenue of $239,000.
How many shares of Insight Molecular Diagnostics are outstanding?
Insight Molecular Diagnostics reported a weighted average of 36.8 million basic shares outstanding in 2026 Q2.
What is Insight Molecular Diagnostics' market cap?
Based on its latest closing price, Insight Molecular Diagnostics (IMDX) has a market capitalization of about $109.9M.
When does Insight Molecular Diagnostics' fiscal year end?
Insight Molecular Diagnostics' fiscal year end, as registered with the SEC, is December 31.
Where is Insight Molecular Diagnostics headquartered?
Insight Molecular Diagnostics lists its business address in Nashville, Tennessee in its SEC filings.
Insight Molecular Diagnostics Competitors & Similar Companies
See all 15 In Vitro & In Vivo Diagnostic Substances companies →